Rajendar K Mittapalli Selected Research

Rajendar K Mittapalli Research Topics

Disease

19	Neoplasms (Cancer) 01/2021 - 12/2010
18	Breast Neoplasms (Breast Cancer) 01/2017 - 10/2009
16	Brain Neoplasms (Brain Tumor) 01/2017 - 10/2009
5	Glioblastoma (Glioblastoma Multiforme) 01/2017 - 10/2012
5	Melanoma (Melanoma, Malignant) 02/2016 - 07/2012
5	Neoplasm Metastasis (Metastasis) 11/2013 - 10/2009
4	Glioma (Gliomas) 01/2016 - 10/2012
2	Body Weight (Weight, Body) 01/2017 - 10/2015
2	Leukemia 04/2013 - 04/2013
1	Rheumatoid Arthritis 01/2019
1	Disease Progression 10/2018
1	Fatigue 01/2018
1	Edema (Dropsy) 01/2017
1	Fallopian Tube Neoplasms 01/2017
1	Rectal Neoplasms (Rectal Cancer) 01/2017
1	Sarcoma (Soft Tissue Sarcoma) 08/2014
1	Brain Diseases (Brain Disorder) 06/2013
1	Renal Cell Carcinoma (Grawitz Tumor) 06/2013
1	Vascular Remodeling 12/2010
1	Dementia (Dementias) 10/2010
1	Neoplasm Micrometastasis 10/2009

Drug/Important Bio-Agent (IBA)

13	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 02/2016 - 12/2010
12	Proteins (Proteins, Gene)FDA Link 02/2016 - 12/2010
10	Pharmaceutical PreparationsIBA 02/2016 - 10/2009
4	ErbB Receptors (EGF Receptor)IBA 01/2019 - 10/2015
4	ElacridarIBA 01/2016 - 04/2013
3	Immunoconjugates (Immunoconjugate)IBA 01/2019 - 05/2017
3	VemurafenibIBA 02/2015 - 07/2012
3	Sunitinib (Sutent)FDA Link 12/2013 - 06/2013
3	Paclitaxel (Taxol)FDA LinkGeneric 11/2013 - 11/2009
2	Phosphotransferases (Kinase)IBA 01/2021 - 10/2012
2	Cytotoxins (Cytolysins)IBA 01/2019 - 01/2018
2	depatuxizumab mafodotinIBA 01/2019 - 01/2018
2	EpitopesIBA 01/2019 - 10/2015
2	ABT-767IBA 10/2018 - 01/2017
2	Poly(ADP-ribose) Polymerase InhibitorsIBA 10/2018 - 12/2015
2	Monoclonal AntibodiesIBA 01/2018 - 10/2015
2	AlbuminsIBA 01/2017 - 10/2015
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2016 - 08/2014
2	Mitogen-Activated Protein KinasesIBA 02/2016 - 08/2014
2	Dasatinib (BMS 354825)FDA Link 01/2016 - 10/2012
2	dabrafenibIBA 08/2014 - 03/2013
2	Tyrosine Kinase InhibitorsIBA 12/2013 - 06/2013
1	Antimitotic AgentsIBA 01/2019
1	Delayed-Action PreparationsIBA 01/2019
1	Janus KinasesIBA 01/2019
1	monomethylauristatin FIBA 01/2019
1	upadacitinibIBA 01/2019
1	PlatinumIBA 10/2018
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 10/2018
1	ABT-414IBA 05/2017
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2017
1	CreatinineIBA 01/2017
1	Trastuzumab (Herceptin)FDA Link 01/2017
1	Bevacizumab (Avastin)FDA Link 01/2017
1	veliparibIBA 01/2017
1	AntibodiesIBA 01/2017
1	Capecitabine (Xeloda)FDA Link 01/2017
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 02/2016
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 02/2016
1	omipalisibIBA 02/2016
1	TOR Serine-Threonine KinasesIBA 02/2016
1	Proto-Oncogene Proteins c-sis (Platelet Derived Growth Factor B)IBA 01/2016
1	rucaparibIBA 12/2015
1	Temozolomide (Temodar)FDA LinkGeneric 12/2015
1	Cyclin-Dependent Kinase 4IBA 11/2015
1	palbociclibIBA 11/2015
1	depatuxizumabIBA 10/2015
1	epidermal growth factor receptor VIIIIBA 10/2015
1	trametinibIBA 08/2014
1	Hyaluronic Acid (Hyaluronan)IBA 11/2013
1	NanoconjugatesIBA 11/2013
1	Sorafenib (BAY 43-9006)FDA Link 06/2013
1	CytokinesIBA 06/2013
1	antineoplaston A10 (A 10)IBA 04/2013
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 03/2013
1	Glutamic Acid (Glutamate)FDA Link 03/2013
1	Protein Kinases (Protein Kinase)IBA 03/2013
1	Threonine (L-Threonine)FDA Link 03/2013
1	Valine (L-Valine)FDA Link 03/2013
1	Rhodamine 123IBA 01/2013
1	PropaneIBA 07/2012
1	SulfonamidesIBA 07/2012
1	Lapatinib (GW572016)FDA Link 03/2012
1	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2010
1	Saquinavir (Invirase)FDA Link 12/2010
1	DesminIBA 12/2010
1	Multidrug Resistance-Associated ProteinsIBA 12/2010
1	Angiopep-2IBA 11/2009
1	paclitaxel-Angiopep-2 conjugateIBA 11/2009
1	Vorinostat FDA Link 10/2009
1	Histones (Histone)IBA 10/2009

Therapy/Procedure

7	Therapeutics 02/2016 - 10/2009
5	Drug Therapy (Chemotherapy) 01/2016 - 10/2009
1	Radiotherapy 01/2017
1	Lasers (Laser) 12/2015
1	Intravenous Infusions 10/2015
1	Injections 11/2013
1	Oral Administration 03/2012
1	Highly Active Antiretroviral Therapy (HAART) 10/2010